BACKGROUND: It is unknown whether adverse birth outcomes are associated with maternal highly active antiretroviral therapy (HAART) in pregnancy, particularly in resource-limited settings. METHODS: We abstracted obstetrical records at 6 sites in Botswana for 24 months. Outcomes included stillbirths (SBs), preterm delivery (PTD), small for gestational age (SGA), and neonatal death (NND). Among human immunodeficiency virus (HIV)-infected women, comparisons were limited to HAART exposure status at conception, and those with similar opportunities for outcomes. Comparisons were adjusted for CD4(+) lymphocyte cell count. RESULTS: Of 33,148 women, 32,113 (97%) were tested for HIV, of whom 9504 (30%) were HIV infected. Maternal HIV was significantly associated with SB, PTD, SGA, and NND. Compared with all other HIV-infected women, those continuing HAART from before pregnancy had higher odds of PTD (adjusted odds ratio [AOR], 1.2; 95% confidence interval [CI], 1.1, 1.4), SGA (AOR, 1.8; 95% CI, 1.6, 2.1) and SB (AOR, 1.5; 95% CI, 1.2, 1.8). Among women initiating antiretroviral therapy in pregnancy, HAART use (vs zidovudine) was associated with higher odds of PTD (AOR, 1.4; 95% CI, 1.2, 1.8), SGA (AOR, 1.5; 95% CI, 1.2, 1.9), and SB (AOR, 2.5; 95% CI, 1.6, 3.9). Low CD4(+) was independently associated with SB and SGA, and maternal hypertension during pregnancy with PTD, SGA, and SB. CONCLUSIONS: HAART receipt during pregnancy was associated with increased PTD, SGA, and SB.
BACKGROUND: It is unknown whether adverse birth outcomes are associated with maternal highly active antiretroviral therapy (HAART) in pregnancy, particularly in resource-limited settings. METHODS: We abstracted obstetrical records at 6 sites in Botswana for 24 months. Outcomes included stillbirths (SBs), preterm delivery (PTD), small for gestational age (SGA), and neonatal death (NND). Among human immunodeficiency virus (HIV)-infectedwomen, comparisons were limited to HAART exposure status at conception, and those with similar opportunities for outcomes. Comparisons were adjusted for CD4(+) lymphocyte cell count. RESULTS: Of 33,148 women, 32,113 (97%) were tested for HIV, of whom 9504 (30%) were HIV infected. Maternal HIV was significantly associated with SB, PTD, SGA, and NND. Compared with all other HIV-infectedwomen, those continuing HAART from before pregnancy had higher odds of PTD (adjusted odds ratio [AOR], 1.2; 95% confidence interval [CI], 1.1, 1.4), SGA (AOR, 1.8; 95% CI, 1.6, 2.1) and SB (AOR, 1.5; 95% CI, 1.2, 1.8). Among women initiating antiretroviral therapy in pregnancy, HAART use (vs zidovudine) was associated with higher odds of PTD (AOR, 1.4; 95% CI, 1.2, 1.8), SGA (AOR, 1.5; 95% CI, 1.2, 1.9), and SB (AOR, 2.5; 95% CI, 1.6, 3.9). Low CD4(+) was independently associated with SB and SGA, and maternal hypertension during pregnancy with PTD, SGA, and SB. CONCLUSIONS: HAART receipt during pregnancy was associated with increased PTD, SGA, and SB.
Authors: Edgardo G Szyld; Eduardo M Warley; Laura Freimanis; René Gonin; Pedro E Cahn; Guilherme A Calvet; Geraldo Duarte; Victor H Melo; Jennifer S Read Journal: AIDS Date: 2006-11-28 Impact factor: 4.177
Authors: Anna Suy; Esteban Martínez; Oriol Coll; Montserrat Lonca; Montserrat Palacio; Elisa de Lazzari; María Larrousse; Ana Milinkovic; Sandra Hernández; José L Blanco; Josep Mallolas; Agathe León; Juan A Vanrell; José M Gatell Journal: AIDS Date: 2006-01-02 Impact factor: 4.177
Authors: Nigel C Rollins; Hoosen M Coovadia; Ruth M Bland; Anna Coutsoudis; Michael L Bennish; Deven Patel; Marie-Louise Newell Journal: J Acquir Immune Defic Syndr Date: 2007-03-01 Impact factor: 3.731
Authors: K Boer; J F Nellen; D Patel; S Timmermans; C Tempelman; M Wibaut; M A Sluman; M E van der Ende; M H Godfried Journal: BJOG Date: 2007-02 Impact factor: 6.531
Authors: Kristina Adachi; Jeffrey D Klausner; Jiahong Xu; Bonnie Ank; Claire C Bristow; Mariza G Morgado; D Heather Watts; Fred Weir; David Persing; Lynne M Mofenson; Valdilea G Veloso; Jose Henrique Pilotto; Esau Joao; Glenda Gray; Gerhard Theron; Breno Santos; Rosana Fonseca; Regis Kreitchmann; Jorge Pinto; Marisa M Mussi-Pinhata; Mariana Ceriotto; Daisy Maria Machado; Yvonne J Bryson; Beatriz Grinsztejn; Francisco I Bastos; George Siberry; Karin Nielsen-Saines Journal: Pediatr Infect Dis J Date: 2016-08 Impact factor: 2.129
Authors: Angela M Bengtson; Daniel Westreich; Patrick Musonda; Audrey Pettifor; Carla Chibwesha; Benjamin H Chi; Bellington Vwalika; Brian W Pence; Jeffrey S A Stringer; William C Miller Journal: Epidemiology Date: 2016-09 Impact factor: 4.822
Authors: Ellen C Caniglia; Rebecca Zash; Sonja A Swanson; Kathleen E Wirth; Modiegi Diseko; Gloria Mayondi; Shahin Lockman; Mompati Mmalane; Joseph Makhema; Scott Dryden-Peterson; Kalé Z Kponee-Shovein; Oaitse John; Eleanor J Murray; Roger L Shapiro Journal: Am J Epidemiol Date: 2019-09-01 Impact factor: 4.897
Authors: Ellen C Caniglia; Rebecca Zash; Denise L Jacobson; Modiegi Diseko; Gloria Mayondi; Shahin Lockman; Jennifer Y Chen; Mompati Mmalane; Joseph Makhema; Miguel A Hernán; Roger L Shapiro Journal: AIDS Date: 2018-01-02 Impact factor: 4.177